William L Heaton Selected Research

BP-5-087

3/2015

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

William L Heaton Research Topics

Disease

3	Neoplasms (Cancer) 01/2019 - 03/2015
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 04/2016 - 03/2015
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 01/2019
2	Primary Myelofibrosis (Myelosclerosis) 01/2019 - 11/2018
2	Philadelphia Chromosome 03/2015 - 09/2014
2	Leukemia 03/2015 - 09/2014
1	Fibrosis (Cirrhosis) 01/2019
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2019

Drug/Important Bio-Agent (IBA)

4	Phosphotransferases (Kinase)IBA 04/2016 - 09/2014
4	Tyrosine Kinase InhibitorsIBA 04/2016 - 09/2014
1	Lysine (L-Lysine)FDA Link 01/2021
1	Reticulin (Reticular Fiber)IBA 01/2019
1	Histone Deacetylase InhibitorsIBA 01/2019
1	AES-135IBA 01/2019
1	EltanexorIBA 01/2019
1	ruxolitinibIBA 01/2019
1	selinexorIBA 01/2019
1	Janus Kinase InhibitorsIBA 01/2019
1	Histone Deacetylases (Histone Deacetylase)IBA 01/2019
1	Hydroxamic Acids (Hydroxamic Acid)IBA 01/2019
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2018
1	BP-5-087IBA 03/2015
1	ponatinibIBA 09/2014

Therapy/Procedure

3	Therapeutics 01/2019 - 03/2015